about
The redefinition of aging in American surgeryThe rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public healthA definition and ethical evaluation of overdiagnosis.Overdiagnosis, medicalisation and social justice: commentary on Carter et al (2016) 'A definition and ethical evaluation of overdiagnosis'.Risk, reassurance and routine: a qualitative study of narrative understandings of the potential for HIV self-testing among men who have sex with men in England.The pursuit of preventive care for chronic illness: turning healthy people into chronic patients.Uncertain Futures: Individual Risk and Social Context in Decision-Making in Cancer Screening.A diagnostic illusory? The case of distinguishing between "vegetative" and "minimally conscious" statesDeveloping a framework for implementation of genetic services: learning from examples of testing for monogenic forms of common diseases.Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test resultMaking birth defects 'preventable': pre-conceptional vitamin supplements and the politics of risk reduction.Risk of cardiovascular disease? A qualitative study of risk interpretation among patients with high cholesterol.What we talk about when we talk about risk: refining surgery's hazards in medical thoughtGaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative studyBiomarkers, the molecular gaze and the transformation of cancer survivorship.Examining critical health policy issues within and beyond the clinical encounter: patient-provider relationships and help-seeking behaviors.Patients-in-waiting: Living between sickness and health in the genomics era.LIFESTAT - Living with statins: An interdisciplinary project on the use of statins as a cholesterol-lowering treatment and for cardiovascular risk reduction.Measuring personal chemical exposures through biomonitoring: the experiences of research participants.What is wrong with 'being a pill-taker'? The special case of statins.Reacting to genetic risk: an experimental survey of life between health and disease.The Irrelevance Narrative: Queer (In)Visibility in Medical Education and Practice.The risk experience: the social effects of health screening and the emergence of a proto-illness.How medical technologies shape the experience of illness.Primary goals, information-giving and men's understanding: a qualitative study of Australian and UK doctors' varied communication about PSA screening.Mothers' appreciation of chromosomal microarray analysis for autism spectrum disorder.Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.Diagnosis, narrative identity, and asymptomatic disease.Identity, community and care in online accounts of hereditary colorectal cancer syndrome.PSA testing: Molecular technologies and men's experience of prostate cancer survivorship
P2860
Q27009115-8744AF8D-9CE4-4D50-8AF9-30F9E18EB549Q27015179-33C4E5D0-2479-4143-A32A-2EB7B014BE14Q30390396-7F88C25E-8E4A-4E3B-BC5D-11BE7F75EB4BQ30391614-8631D399-C71A-4B47-805F-9035571A2E06Q33716554-6A8BCE28-8BC1-4DC9-8138-759F86F690F1Q33818794-AF95BE8C-76E4-4FF2-82BD-778309634D57Q33916847-B8CC44F3-5A88-40E2-B434-8EDBE25E6A27Q34013469-94D628D7-BC8F-4F5B-B6F8-E66B9720EC55Q34156862-A1EE69AF-7CD7-4B1D-92B7-978FD87A7B56Q34722573-BBE30BF6-0741-4AC4-B2C4-439C7753EACEQ34767178-425A5525-8430-481D-9314-7165DB763A4FQ34990793-5EFF4EA1-F966-432C-B5F6-0EF74FA9B6F7Q36063770-809AD668-B96C-4F95-B5A2-E7B43875EA40Q36172491-FA1FDC00-B372-4B30-8921-CEBA32D986E8Q36898947-3B4D6E12-A7CC-4D55-BAC0-BA7EBF2064D0Q37799913-D4B90D46-4573-4657-86E6-DC475AB1D700Q37816055-9C34DE2C-2424-45CF-AE42-8CC9B10361EEQ38900467-B6A55ADE-D89E-452A-B6B8-3D218E961500Q39248554-DA0054E7-E839-4913-ACAA-832567D6CBE7Q39362025-5F8FC176-D00B-4B9C-A47D-F075364A46BCQ45847055-6ED59336-6C37-43B8-B5FD-594C385C049AQ47325385-3644D54C-A7D9-451A-85FC-6AB025078ADCQ48084604-87A59171-2EFB-4D04-8352-E202E6E8E18FQ48110645-94BCF4B5-9850-46DB-A5D2-B22A79CF0CE4Q48181534-16E77552-1133-43A7-A867-7AE605249A2DQ50310101-686E6FAC-07DB-473B-9015-3FD442B41265Q50421914-72764B0B-0F2B-44E7-B0F2-D9C46E5F319BQ53769910-F5D8B117-CE46-42D7-BDD4-042475F2F792Q55308471-07EA4D11-AF1A-4BBC-8797-C774BC4294F3Q57603428-3A969B6B-FC8D-4E2F-A26B-F59A2A6AD133
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The converged experience of risk and disease.
@en
The converged experience of risk and disease.
@nl
type
label
The converged experience of risk and disease.
@en
The converged experience of risk and disease.
@nl
prefLabel
The converged experience of risk and disease.
@en
The converged experience of risk and disease.
@nl
P2860
P1433
P1476
The converged experience of risk and disease.
@en
P2093
Robert A Aronowitz
P2860
P304
P356
10.1111/J.1468-0009.2009.00563.X
P407
P577
2009-06-01T00:00:00Z